ModernGraham Valuation

Company Name:

Company Ticker REGN Date of Analysis Regeneron Pharmaceuticals Inc



8/4/2016

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1. Adequate	e Size of the Enterprise	Market Cap > \$2Bil	\$46,218,576,706 Pass
2. Sufficien	tly Strong Financial Condition	Current Ratio > 2	3.41 Pass
3. Earnings	Stability	Positive EPS for 10 years prior	Fail
4. Dividend	Record	Dividend Payments for 10 years pri	or Fail
5. Earnings	Growth	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	-580.81% Fail
6. Moderate	e PEmg Ratio	PEmg < 20	76.12 Fail
7. Moderate	e Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	13.15 Fail
Enterprising Investor; must pass 4	out of the following 5 tests, or b	e suitable for the Defensive Investor.	

· ·	0		
1. Sufficiently Strong Fir	ancial Condition	Current Ratio > 1.5	3.41 Pass
2. Sufficiently Strong Fir	ancial Condition	Debt to NCA < 1.1	0.00 Pass
3. Earnings Stability		Positive EPS for 5 years prior	Pass
4. Dividend Record		Currently Pays Dividend	Fail
5. Earnings Growth		EPSmg greater than 5 years ago	Pass

Suitability

Defensive	No
Enterprising	Yes

Stage 2: Determination of Intrinsic Value

	EPSmg		\$5.69
	MG Growth Estimate		15.00%
	MG Value		\$219.22
	MG Value based on 3% Growth		\$82.56
	MG Value based on 0% Growth		\$48.40
	Market Implied Growth Rate		33.81%
MG Opinion			
	Current Price		\$433.40
	% of Intrinsic Value		197.70%
	Opinion	Overvalued	
	MG Grade	C-	


Stage 3: Information for Further Research

Net Current Asset Value (NCAV)	\$8.70
Graham Number	\$80.54
PEmg	76.12
Current Ratio	3.41
PB Ratio	13.15
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend Growth	0

Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus Morningstar MSN Money Seeking Alpha SEC Filings

EPS History		EPSmg History	
Next Fiscal Year	•• • •		6 - 0
Estimate		Next Fiscal Year Estimate	\$5.69
Dec2015	\$5.52		\$4.12
Dec2014	\$2.98	Dec2014	\$2.92
Dec2013	\$3.72	Dec2013	\$2.33
Dec2012	\$6.75	Dec2012	\$1.16
Dec2011	-\$2.45	Dec2011	-\$1.56
Dec2010	-\$1.26	Dec2010	-\$1.18
Dec2009	-\$0.85	Dec2009	-\$1.22
Dec2008	-\$1.00	Dec2008	-\$1.29
Dec2007	-\$1.59	Dec2007	-\$1.39
Dec2006	-\$1.77	Dec2006	-\$1.3
Dec2005	-\$1.71	Dec2005	-\$1.30
Dec2004	\$0.74	Dec2004	-\$1.17
Dec2003	-\$2.13	Dec2003	-\$1.96
Dec2002	-\$2.83	Dec2002	-\$1.68
Dec2001	-\$1.81	Dec2001	-\$0.99
Dec2000	-\$0.66	Dec2000	-\$0.6
Dec1999	-\$0.74	Balance Sheet Information	3/1/2016
Dec1998	-\$0.28	Total Current Assets	\$3,133,379,000
Dec1997	-\$0.40	Total Current Liabilities	\$919,724,000
Dec1996	-\$1.32	Long-Term Debt	\$0
		Total Assets	\$5,904,460,000
		Intangible Assets	\$0
		Total Liabilities	\$2,139,378,000
		Shares Outstanding (Diluted Average)	114,228,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other Oraham	Regeneron Pharmaceuticals Inc. Annual Valuation – 2015 \$REGN
ModernGraham posts about the	16 Companies in the Spotlight this Week – 4/19/14
company	Regeneron Pharmaceuticals Inc. (REGN) Annual Valuation – 2014

Other ModernGraham posts about related companies	AmerisourceBergen Corp Valuation – July 2016 \$ABC
	Perrigo Co PLC Valuation – July 2016 \$PRGO
	AbbVie Inc Valuation – July 2016 \$ABBV
	Gilead Sciences Inc Valuation – July 2016 \$GILD
	Eli Lilly and Company Valuation – July 2016 \$LLY
	Zoetis Inc Valuation – June 2016 \$ZTS
	Merck & Co Inc Valuation – March 2016 \$MRK
	Bristol-Myers Squibb Company Valuation – February 2016 \$BMY
	Amgen Inc Valuation – February 2016 \$AMGN
	Merck & Co Inc Valuation – March 2016 \$MRK